BRCA2 and ovarian cancer: This suggests that a tailored clinical approach may be necessary for BRCA 2 mutation-associated prostate cancer, similar to the personalized therapeutic approach for BRCA2-associated breast and ovarian cancers, both of which are particularly sensitive to platinum-based.